Laurence Collette

Summary

Affiliation: EORTC Data Center
Country: Belgium

Publications

  1. ncbi request reprint Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder
    Philip M Poortmans
    Department of Radiation Oncology, Dr Bernard Verbeeten Institute, Tilburg, The Netherlands
    Acta Oncol 47:937-40. 2008
  2. ncbi request reprint Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Rad
    Laurence Collette
    Statistics Department, European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 25:4379-86. 2007
  3. ncbi request reprint Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials
    Laurence Collette
    European Organisation for Research and Treatment of Cancer EORTC Data Center, Avenue E Mounier 83 11, 1200 Brusells, Biostatistics Department, Brussels, Belgium
    Eur J Cancer 42:1344-50. 2006
  4. ncbi request reprint Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)
    Laurence Collette
    European Organisation for Research and Treatment of Cancer EORTC Data Center Biostatistics, Avenue E Mounier 83 11, B 1200, Brussels, Belgium
    Eur J Cancer 41:2662-72. 2005
  5. ncbi request reprint Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and
    Laurence Collette
    European Organization for Research and Treatment of Cancer Data Center, Avenue Emmanuel Mounier 83 11, B 1200 Brussels, Belgium
    J Clin Oncol 23:6139-48. 2005
  6. doi request reprint Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)
    Oscar Matzinger
    European Organisation for Research and Treatment of Cancer EORTC, Headquarters, Brussels, Belgium
    Acta Oncol 49:24-34. 2010
  7. doi request reprint One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
    Vasiliki Pasoglou
    Department of Radiology, Centre du Cancer et Institut de Recherche Expérimentale et Clinique IREC, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Prostate 74:469-77. 2014
  8. ncbi request reprint Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group
    Laurence Collette
    European Organisation for Research and Treatment of Cancer, Data Center Biostatistics, Ave E Mounier 83 11, B 1200 Brussels, Belgium
    J Clin Oncol 22:3877-85. 2004
  9. ncbi request reprint Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)
    Laurence Collette
    EORTC Data Center, Rue E Mounier 83, B 11, B 1200 Brussels, Belgium
    Eur Urol 44:182-9; discussion 189. 2003
  10. ncbi request reprint Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: results of the Dummy Run procedure
    Paul A Fenton
    EORTC Headquarters, Brussels, Belgium
    Radiother Oncol 107:346-51. 2013

Detail Information

Publications48

  1. ncbi request reprint Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder
    Philip M Poortmans
    Department of Radiation Oncology, Dr Bernard Verbeeten Institute, Tilburg, The Netherlands
    Acta Oncol 47:937-40. 2008
    ..We prospectively evaluated concomitant radiotherapy and chemotherapy for advanced bladder cancer in a phase II EORTC trial to test whether it could be further studied as a potential treatment of bladder cancer...
  2. ncbi request reprint Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Rad
    Laurence Collette
    Statistics Department, European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 25:4379-86. 2007
    ..We further explored the data with the aim of refining our understanding of the long-term results...
  3. ncbi request reprint Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials
    Laurence Collette
    European Organisation for Research and Treatment of Cancer EORTC Data Center, Avenue E Mounier 83 11, 1200 Brusells, Biostatistics Department, Brussels, Belgium
    Eur J Cancer 42:1344-50. 2006
    ..We give some recommendations for the planning of trials that would use PSA endpoints (in hormone refractory disease) and for the early stop of (endocrine treatment) trials on the basis of intermediate results based on PSA...
  4. ncbi request reprint Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)
    Laurence Collette
    European Organisation for Research and Treatment of Cancer EORTC Data Center Biostatistics, Avenue E Mounier 83 11, B 1200, Brussels, Belgium
    Eur J Cancer 41:2662-72. 2005
    ..Postoperative irradiation improved biochemical progression-free survival in all patient groups. Longer follow-up is needed to assess the endpoint of clinical progression-free survival...
  5. ncbi request reprint Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and
    Laurence Collette
    European Organization for Research and Treatment of Cancer Data Center, Avenue Emmanuel Mounier 83 11, B 1200 Brussels, Belgium
    J Clin Oncol 23:6139-48. 2005
    ..It could be shortened by using surrogate end points. Prostate-specific antigen (PSA) is the most studied biomarker in prostate cancer (PCa). This study attempts to validate PSA end points as surrogates for OS in advanced PCa...
  6. doi request reprint Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)
    Oscar Matzinger
    European Organisation for Research and Treatment of Cancer EORTC, Headquarters, Brussels, Belgium
    Acta Oncol 49:24-34. 2010
    ..We present the toxicity reported until year 3 after treatment...
  7. doi request reprint One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
    Vasiliki Pasoglou
    Department of Radiology, Centre du Cancer et Institut de Recherche Expérimentale et Clinique IREC, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Prostate 74:469-77. 2014
    ..Whole-body MRI (wbMRI) has shown capabilities for metastatic screening. This study assesses the feasibility and value of an all-in-one AJCC TNM staging of PCa during a unique MRI session combining mpMRI and wbMRI...
  8. ncbi request reprint Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group
    Laurence Collette
    European Organisation for Research and Treatment of Cancer, Data Center Biostatistics, Ave E Mounier 83 11, B 1200 Brussels, Belgium
    J Clin Oncol 22:3877-85. 2004
    ....
  9. ncbi request reprint Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)
    Laurence Collette
    EORTC Data Center, Rue E Mounier 83, B 11, B 1200 Brussels, Belgium
    Eur Urol 44:182-9; discussion 189. 2003
    ..We study the value of PSA response and PSA progression as prognostic factors for survival in good prognosis metastatic prostate cancer...
  10. ncbi request reprint Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: results of the Dummy Run procedure
    Paul A Fenton
    EORTC Headquarters, Brussels, Belgium
    Radiother Oncol 107:346-51. 2013
    ..As part of the quality assurance of radiotherapy (QART) a Dummy Run (DR) procedure was performed...
  11. ncbi request reprint Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes
    Elena Musat
    EORTC, Avenue E Mounierlaan, 83 11, 1200 Brussels, Belgium
    Eur J Cancer 43:718-24. 2007
    ..In the final trial analysis, a sensitivity analysis should evaluate the subgroup of patients receiving an optimal treatment to verify the robustness of the results and the true impact of IM-MS irradiation...
  12. ncbi request reprint Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863
    Fatma Ataman
    EORTC Data Center, Radiotherapy Group, Avenue E Mounier 83, Bte 11, B 1200 Brussels, Belgium
    Eur J Cancer 40:1674-81. 2004
    ..Although four treatment-related deaths (1%) occurred, grade 3 or 4 late complications were less than 5%...
  13. doi request reprint Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
    Frederic E Lecouvet
    Department of Radiology, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Eur Urol 62:68-75. 2012
    ..However, this two-step approach has limited sensitivity and specificity...
  14. ncbi request reprint EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach
    Oscar Matzinger
    EORTC Headquarters, Brussels, Belgium
    Radiother Oncol 92:164-75. 2009
    ..The Gastro-Intestinal Working Party of the EORTC Radiation Oncology Group (GIWP-ROG) developed guidelines for target volume definition in neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction (GEJ) and the stomach...
  15. doi request reprint Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century
    Tom Budiharto
    EORTC Head Quarters, Brussels, Belgium
    Radiother Oncol 88:403-10. 2008
    ..The first step is the evaluation of the structure and of the human, technical and organisational resources of the centres, to assess their ability to comply with the current requirements for high-tech radiotherapy (RT)...
  16. ncbi request reprint What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?
    Cora N Sternberg
    San Camillo and Forlanini Hospitals, Rome, Italy, and EORTC Data Center, Biostatistics Department, Brussels, Belgium
    BJU Int 98:487-9. 2006
  17. doi request reprint Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'
    Sandra Collette
    Statistics Department, EORTC Headquarters, Brussels, Belgium
    Eur J Cancer 44:2587-99. 2008
    ..01) if WBI was given with >6 MV photons. The c-index was around 0.62. Nomograms with these factors are proposed to forecast the long-term risk of moderate or severe fibrosis...
  18. pmc Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study
    Jean Luc Van Laethem
    Department of Gastroenterology, Erasme University Hospital, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 28:4450-6. 2010
    ..This randomized phase II intergroup study explores the feasibility and tolerability of a gemcitabine-based CRT regimen after R0 resection of pancreatic head cancer...
  19. ncbi request reprint Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 109:2004-10. 2007
    ....
  20. ncbi request reprint Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials
    Laurence Collette
    Eur Urol 53:6-9. 2008
  21. ncbi request reprint Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC trial 22921
    Marcel den Dulk
    Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
    Eur J Cancer 43:1821-8. 2007
    ....
  22. ncbi request reprint Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial
    Harry Bartelink
    Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 25:3259-65. 2007
    ..To investigate the long-term impact of a boost radiation dose of 16 Gy on local control, fibrosis, and overall survival for patients with stage I and II breast cancer who underwent breast-conserving therapy...
  23. ncbi request reprint Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911
    Theodorus H van der Kwast
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University Health Network, Toronto, Canada
    J Clin Oncol 25:4178-86. 2007
    ..Review pathology data of specimens from participants in this trial were analyzed to identify which factors predict increased benefit from adjuvant radiotherapy...
  24. ncbi request reprint Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer
    Theodorus H van der Kwast
    J Clin Oncol 25:5671-2. 2007
  25. doi request reprint Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)
    Urs E Studer
    Department of Urology, University Hospital of Bern, Switzerland
    Eur Urol 53:941-9. 2008
    ..The question arises whether serum prostate-specific antigen (PSA) levels may be used to decide when to initiate ADT in PCa not suitable for local curative treatment...
  26. ncbi request reprint Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892
    Fritz H Schroder
    Department of Urology, Erasmus MC, P O Box 2040 3000 CA Rotterdam, The Netherlands
    Eur Urol 45:457-64. 2004
    ..The results pertaining to sexual function were already reported [Br J Cancer 82(2) (2000) 283]...
  27. ncbi request reprint Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
    Laurence Collette
    J Clin Oncol 25:5673-4; author reply 5674. 2007
  28. ncbi request reprint Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882
    Ninja Antonini
    Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Radiother Oncol 82:265-71. 2007
    ..To determine whether the effect of an additional "boost" radiation after breast conservative therapy (BCT) on local control depends on age and evaluate the impact of a treatment policy with a threshold for age...
  29. ncbi request reprint Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
    Michel Bolla
    University Hospital, Grenoble, France
    Lancet 360:103-6. 2002
    ....
  30. ncbi request reprint EORTC prostate cancer trials: what have we learnt?
    Theo M de Reijke
    Department of Urology, Academic Medical Center, Meibergdreef 9, Amsterdam, The Netherlands
    Crit Rev Oncol Hematol 43:159-65. 2002
    ....
  31. ncbi request reprint Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20)
    Sophie D Fossa
    Norwegian Radium Hospital, Oslo, Norway
    J Clin Oncol 21:1107-18. 2003
    ..To describe global quality of life (GLQL) in patients with metastatic testicular cancer (TC) treated with four different schedules of bleomycin, etoposide, and cisplatin (BEP) chemotherapy (four v three cycles given over 5 v 3 days)...
  32. ncbi request reprint Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study
    Walter Albrecht
    Department of Urology, Rudolfstiftung, Juchgasse 25, A 1030, Vienna, Austria
    Eur Urol 44:505-11. 2003
    ..In preparation of an intercontinental Phase III trial comparing continuous maximal androgen blockade (MAB) to intermittent androgen suppression (IAS) in untreated metastatic prostate cancer, a feasibility study on IAS was accomplished...
  33. ncbi request reprint Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Urol 172:923-7. 2004
    ..The issue is addressed in protocol 30846 of the European Organisation for Research and Treatment of Cancer for patients with lymph node positive cancer without local treatment of the primary tumor...
  34. ncbi request reprint Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period
    Philip M P Poortmans
    Department of Radiotherapy, Dr Bernard Verbeeten Instituut, Tilburg, The Netherlands
    Radiother Oncol 76:278-84. 2005
    ..To evaluate the impact of quality assurance on treatment compliance, we compared the outcome of the two individual case reviews (ICR) conducted early and late during the accrual period of a large prospective multi-centre trial...
  35. ncbi request reprint Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921
    Jean Francois Bosset
    Centre Hospitalier Universitaire Besançon, France
    J Clin Oncol 23:5620-7. 2005
    ..We investigated the effect of adding CT on the pathologic parameters...
  36. ncbi request reprint Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)
    Michel Bolla
    Department of Radiation Oncology, Centre Hospitalier Universitaire A Michallon, Grenoble, France
    Lancet 366:572-8. 2005
    ..We did a randomised controlled trial to compare radical prostatectomy followed by immediate external irradiation with prostatectomy alone for patients with positive surgical margin or pT3 prostate cancer...
  37. ncbi request reprint Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911)
    Theodorus H van der Kwast
    Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada, and Department of Urology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Virchows Arch 449:428-34. 2006
    ..05 and p>0.8). The observations suggest that review of pathological stage and surgical margin of radical prostatectomy strongly improves their prognostic impact in multi-institutional studies or trials...
  38. ncbi request reprint Prophylactic cranial irradiation in extensive small-cell lung cancer
    Ben Slotman
    Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    N Engl J Med 357:664-72. 2007
    ..We conducted a randomized trial of prophylactic cranial irradiation in patients with extensive small-cell lung cancer who had had a response to chemotherapy...
  39. ncbi request reprint Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works
    Philip Poortmans
    Department of Radiotherapy, Dr Bernard Verbeeten Instituut, Tilburg, The Netherlands
    Strahlenther Onkol 182:576-82. 2006
    ..The results of a dummy run procedure and of an individual case review are compared to each other. The effects of recommendations based on QA procedures on the protocol compliance are evaluated...
  40. ncbi request reprint Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy
    Urs E Studer
    Eur Urol 50:887-9; discussion 889-92. 2006
  41. ncbi request reprint Chemotherapy with preoperative radiotherapy in rectal cancer
    Jean Francois Bosset
    Department of Radiation Therapy, University of Franche Comte, Besancon, France
    N Engl J Med 355:1114-23. 2006
    ..Preoperative radiotherapy is recommended for selected patients with rectal cancer. We evaluated the addition of chemotherapy to preoperative radiotherapy and the use of postoperative chemotherapy in the treatment of rectal cancer...
  42. ncbi request reprint Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891
    Urs E Studer
    Department of Urology, University Hospital of Bern, Bern, Switzerland
    J Clin Oncol 24:1868-76. 2006
    ..This study (EORTC 30891) attempted to demonstrate equivalent overall survival in patients with localized prostate cancer not suitable for local curative treatment treated with immediate or deferred androgen ablation...
  43. ncbi request reprint Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer
    Massimo Maffezzini
    Department of Urology, Ospedali Galliera, Genoa, Italy
    Eur Urol 51:605-13; discussion 613. 2007
    ..To review the methodology of PSA doubling time (PSA DT) calculations and the implications of PSA DT for the follow-up of prostate cancer patients curatively treated with surgery or radiation therapy...
  44. ncbi request reprint The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial
    Philip Poortmans
    Department of Radiotherapy, Dr Bernard Verbeeten Institute, Tilburg, The Netherlands
    Radiother Oncol 72:25-33. 2004
    ..This paper investigates the potential impact of the different boost techniques on local control and on fibrosis after breast conserving therapy...
  45. ncbi request reprint Clinical trial designs for predictive marker validation in cancer treatment trials
    Daniel J Sargent
    Mayo Clinic, Kahler 1A, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 23:2020-7. 2005
    ..We discuss the advantages and disadvantages of the two trial designs and their appropriateness to specific clinical situations to assist investigators seeking to design rigorous, marker-based clinical trials...
  46. ncbi request reprint Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies
    Maurizio Brausi
    Institute Sant Agostino, Estense, Modena, Italy
    Eur Urol 41:523-31. 2002
    ..To assess the variability between institutions in the recurrence rate at the first follow-up cystoscopy (RR-FFC) after transurethral resection (TUR) in patients with stage Ta T1 bladder cancer...
  47. ncbi request reprint Palliative-care trials: how best to publish findings?
    Murielle E Mauer
    Lancet Oncol 9:411-2. 2008
  48. pmc Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
    Bernard Nordlinger
    centre hospitalier universitaire Ambroise Paré, Assistance Publique Hopitaux de Paris, Departments of Surgery and Oncology, Boulogne Billancourt, France
    Lancet 371:1007-16. 2008
    ..We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer...